Mitsubishi

About: Mitsubishi is a company organization based out in Tokyo, Japan. It is known for research contribution in the topics: Signal & Layer (electronics). The organization has 53115 authors who have published 54821 publications receiving 870150 citations. The organization is also known as: Mitsubishi Group of Companies & Mitsubishi Companies.

Data integrity verifying circuit for electrically erasable and programmable read only memory (EEPROM)

Abstract: An EEPROM provided with a write/erase checking circuit comprising, a data detector for determining whether one byte in an input data contains a "0" (representing that a memory cell is not in an erase state); an address latch circuit and a data latch circuit which latch the address and the input data, respectively, responsive to a detection signal from the data detector; a data read circuit which selects the memory cells according to the address stored in the address latch circuit and reads the data out of the memory cells at the data write checking; and a comparator which compares the data from the data read circuit with the data stored in the data latch circuit.

Programmable logic array having a changeable logic structure

Abstract: Programmable Logic Array PLA) cells are arranged at intersections of input lines and output lines of the array. Particular PLA cells to be programmed are arbitrarily selected by word line and bit line decoders. Switches for programming the PLA cells to implement a desired logic function are controlled by data stored in a random access memory whereby programming of the PLA can be changed arbitrarily and during operation of a system including the PLA.

Apparatus and process for removing carbon dioxide from combustion exhaust gas

Abstract: An apparatus and a process for removing CO₂ from a combustion exhaust gas, which comprises effecting a counterflow contact of the aqueous alkanolamine solution with the combustion exhaust gasto attain removal of CO₂ from said gas and effecting a further contact of either (1) the condensate waterformed by causing condensation of the gas having been subjected to the removal of CO₂ or (2) the condensate water formed by causing condensation of the combustion exhaust gas originated from the combustion of the fuel with the combustion exhaust gas, as the first and the second aspect of the invention; an apparatus for removing CO₂ from a combustion exhaust gas, which comprises a first contact means disposed in said exhaust line for effecting a counterflow contact of the aqueous alkanolamine solution with the combustion exhaust gas and a second contact means disposed downstream of said first contact means in said exhaust line for effecting a counter flow contact of the reflux water from a spent absorbent liquor regenerating tower with said gas having been subjected to the removal of CO₂, as the third aspect; and a process for removing CO₂ using an apparatus of the above aspect, which comprises adjusting the temperature of the aqueous alkanolamine solution to be supplied to said CO₂-removing means, in such a manner that the temperature of the gas at the entrance of the CO₂-removing means and that at the exit of the CO₂-removing means become the same, as the fourth aspect.

Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan.

Abstract: Long-term safety and efficacy of drug-eluting stents remains controversial. The CREDO-Kyoto registry cohort-2 is a physician-initiated non-company sponsored multi-center registry enrolling consecutive patients undergoing first coronary revascularization in 26 centers in Japan. We compared 3-year outcome between patients treated with sirolimus-eluting stent (SES) only (5092 patients) and bare-metal stent (BMS) only (5405 patients). SES-use as compared with BMS-use was associated with significantly lower adjusted risk for all-cause death [hazard ratio (HR) [95% confidence interval (CI)] 0.72 (0.59–0.87), P = 0.0007], which was mainly driven by the reduction in non-cardiac death [HR (95% CI) 0.64 (0.48–0.85), P = 0.002]. The risk of cardiac death [HR (95% CI) 0.82 (0.63–1.07), P = 0.15], myocardial infarction [HR (95% CI) 0.73 (0.51–1.03), P = 0.07] and definite stent thrombosis [HR (95% CI) 0.62 (0.35–1.09), P = 0.1] was not different between the two groups. Despite longer duration of thienopyridine administration, SES-use was associated with significantly lower risk for bleeding [HR (95% CI) 0.75 (0.6–0.95), P = 0.02] and similar risk for stroke [HR (95% CI) 1.0 (0.75–1.34), P = 1.0]. The risk for target-lesion revascularization (TLR) was markedly lower in the SES group [HR (95% CI) 0.42 (0.36–0.48), P < 0.0001]. The direction and magnitude of the effect of SES relative to BMS in patients presenting acute myocardial infarction (AMI) were similar to those in patients presenting otherwise. In conclusion, SES-use as compared with BMS-use was associated with marked reduction of TLR without any increases in death, myocardial infarction, stent thrombosis, stroke and bleeding in real world clinical practice regardless of clinical presentation including AMI.

Cloning and nucleotide sequences of the linear DNA killer plasmids from yeast

Abstract: The linear DNA killer plasmids (pGKL1 and pGKL2) isolated from a Kluyveromyces lactis killer strain are also maintained and expressed its killer character in Saccharomyces cerevisiae After these killer plasmid DNAs isolated from S cerevisiae were treated with alkali, four terminal fragments from each plasmid DNAs were cloned separately Using these and other cloned DNA fragments, the terminal nucleotide sequences of pGKL2 and the complete nucleotide sequence of pGKL1 were determined The inverted terminal repetitions of 202 bp and 182 bp were found in pGKL1 and pGKL2, respectively The pGKL1 sequence showed an extremely high A + T content of 732% and it contained five large open reading frames The largest of these open reading frame was suggested to code for a membrane-bound precursor of glycoprotein subunit of the killer toxin